價(jià)格 | ¥11700 | ¥15300 | ¥19500 |
包裝 | 25mg | 50mg | 100mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2025-02-14 |
中文名稱(chēng):Nelonicline citrate | 英文名稱(chēng):Nelonicline citrate |
CAS:1026136-84-4 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
產(chǎn)品類(lèi)別: 抑制劑 | |
貨號(hào): T38422 |
名稱(chēng) | Nelonicline citrate |
描述 | Nelonicline citrate (ABT-126) is an orally active and selective α7 nicotinic receptor agonist, demonstrating a high affinity for α7 nAChRs in the human brain (Ki = 12.3 nM). This compound is utilized in the research of schizophrenia and Alzheimer's disease. |
體外活性 | Nelonicline citrate is an agonist that binds with high affinity to α7 nAChRs in human brain (K i = 12.3 nM) and activates currents in Xenopus oocytes expressing recombinant human α7 nAChRs (EC 50 =2 μM; intrinsic activity of 74% relative to acetylcholine). Nelonicline citrate does bind to α3β4* nAChRs in human IMR-32 neuroblastoma cells (K i =60 nM), but has only 12% efficacy at 100,000 nM in a calcium flux assay in these cell. Like some other α7 nAChR agonists, Nelonicline citrate is also a 5-HT3 receptor antagonist, but it has >10-fold lower affinity for this receptor than for α7 nAChRs (K i of 140 nM)[1]. |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
關(guān)鍵字 | ABT-126 Citrate | Nelonicline citrate | ABT 126 Citrate | Nelonicline Citrate | ABT126 Citrate |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 589.8595萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP3年
|
陜西締都新材料有限公司
|
2025-03-06 | |
詢(xún)價(jià) |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2025-03-06 | |
詢(xún)價(jià) |
VIP3年
|
陜西締都醫(yī)藥化工有限公司
|
2025-02-18 |